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Abstract
Background: Receptor for advanced glycation endproducts (RAGE) expression contributes to the impaired
angiogenic response to limb ischemia in diabetes. The aim of this study was to detect the effect of increased
expression of RAGE on the angiogenic response to limb ischemia in diabetes by targeting avb3 integrin with
99mTc-labeled Arg-Gly-Asp (RGD).
Methods: Male wild-type (WT) C57BL/6 mice were either made diabetic or left as control for 2 months when they
underwent femoral artery ligation. Four groups were studied at days 3 to 7 after ligation: WT without diabetes
(NDM) (n = 14), WT with diabetes (DM) (n = 14), RAGE
-/- NDM (n = 16), and RAGE
-/- DM (n = 14). Mice were
injected with
99mTc-HYNIC-RGD and imaged. Count ratios for ischemic/non-ischemic limbs were measured. Muscle
was stained for RAGE, avb3, and lectins.
Results: There was no difference in count ratio between RAGE
-/- and WT NDM groups. Mean count ratio was
lower for WT DM (1.38 ± 0.26) vs. WT NDM (1.91 ± 0.34) (P<0.001). Mean count ratio was lower for the RAGE
-/- DM
group than for RAGE
-/- NDM group (1.75 ± 0.22 vs. 2.02 ± 0.29) (P<0.001) and higher than for the WT DM group
(P<0.001). Immunohistopathology supported the scan findings.
Conclusions: In vivo imaging of avb3 integrin can detect the effect of RAGE on the angiogenic response to limb
ischemia in diabetes.
Background
The prevalence of peripheral artery disease in the gen-
eral population is 12% to 14%, affecting 20% of those
>70 years and contributes to significant morbidity. Limb
ischemia in diabetics takes a particularly malignant
course leading to impaired wound healing, gangrene,
amputations, and even death [1,2]. A major and distinct
adaptive process that contributes to restoring nutrient
blood flow to ischemic limbs is angiogenesis/arteriogen-
esis. Angiogenesis refers to the process of endothelial
sprouting. Arteriogenesis is the formation of larger
“arteriole” like vessels. Both processes are essential for
the development of subsequent collateral growth [3].
Tissue hypoxia activates genes that code for angiogenic
growth factors and cytokines. Investigational studies
have documented the involvement of receptor for
advanced glycation endproducts (RAGE) in the impaired
angiogenic response to limb ischemia in diabetes [4-7].
The expression of avb3 integrin, a cell adhesion recep-
tor that plays a crucial role in the angiogenesis process,
can be targeted with radiolabeled peptides for in vivo
imaging [8]. Comparing in vivo imaging in animals with
genetic alteration of pathways implicated in angiogenesis
allows exploration of downstream effects in live animals.
In this study, we investigated the value of imaging the
e f f e c t so fR A G Ee x p r e s s i o no nt h ea n g i o g e n i cr e s p o n s e
to limb ischemia in live animals. We used
99mTc-labeled
Arg-Gly-Asp (RGD) peptide that targets avb3 integrin
expression occurring during capillary sprouting. Our
hypothesis was that using genetically altered mice,
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License99mTc-labeled RGD imaging can detect in vivo the effect
of RAGE expression on angiogenic response to limb
ischemia in diabetes.
Methods
Experimental protocol
A l la n i m a le x p e r i m e n t sw e r eperformed in accordance
with the approval of the Institutional Animal Care and
Use Committee of Columbia University. Homozygous
male RAGE null (RAGE
-/-) mice (backcrossed >10 gen-
erations into C57BL/6) were generated as described pre-
v i o u s l y[ 9 ] .M a l ew i l d - t y p e( W T )C 5 7 B L / 6m i c ew e r e
obtained (Jackson Laboratories). At age 6 weeks, half of
the WT and half of the RAGE
-/- mice were treated with
streptozotocin (STZ; Sigma). Two months later, all mice
underwent femoral artery (FA) ligation.
Induction of diabetes
Mice were treated with five consecutive daily doses of
STZ dissolved in citrate buffer (55 mg/kg, pH 4.5) via
the intraperitoneal route. One week after the first
dose, glucose levels were assessed by glucometer. The
criteria of two consecutive glucose levels >250 mg/dL
was used to indicate diabetes. If glucose levels were
<250 mg/dL, then the mice received two additional
doses of STZ (55 mg/kg).
Femoral artery ligation
Under isoflurane anesthesia, the hair on the abdominal
wall and pelvis and both upper legs was shaved and the
skin prepped with iodine and alcohol. An incision was
made on the upper thigh of both the left and right legs
of each mouse. The inguinal ligament and the upper
half of the femoral artery were exposed. On the left side,
the vascular bundle was isolated from below the ingu-
inal ligament proximally to just above the bifurcation
into the superficial and deep femoral arteries distally.
The femoral artery was dissected free, and two ligatures
were placed around it with 8/0 non-absorbable sutures
and tied. Both skin incisions were closed with sterile 5/0
nylon suture.
Preparation of radiotracer
Aliquots of 5 μg of HYNIC-RGD were incubated with
0.5 ml of tricine solution (70 mg/ml in distilled water)
and approximately 0.5 ml of
99mTcO4
- solution (50 mCi
=1 , 8 5 0M B q )a n d2 0μl of tin(II) solution (10 mg of
SnCl2·2H2Oi n1 0m lo fn i t r o g e n - p u r g e d0 . 1NH C lf o r
20 min) at room temperature. To test the specificity of
the HYNIC-RGD, cyclo [Arg-Ala-Asp-D-Phe-Lys
(HYNIC)] (Peptides International, Louisville, KY, USA)
was similarly radiolabeled and used as control peptide.
Radiochemical purity was >94% by Tec-control chroma-
tography (Biodex, Shirley, NY, USA).
Injection of radiotracer and imaging
Under isoflurane anesthesia (1.5% isoflurane at a flow
rate of 0.5% L/min oxygen per mouse), a cutdown was
made over the jugular vein and a specially designed vas-
cular catheter was placed (Braintree Scientific, Braintree,
MA, USA). Mice in each of four groups were injected
with
99mTc-HYNIC-RGD and imaged 3 or 7 days after
FA ligation: WT without diabetes (n =1 4 ) ,W Tw i t h
diabetes (n = 14), RAGE
-/- without diabetes (n = 16),
RAGE
-/- with diabetes (n = 14), and five WT without
diabetes were injected with control peptide. All mice
were injected through the jugular vein catheter with 1 ±
0.2 mCi of
99mTc-HYNIC-RGD in 0.05 to 0.1 ml (corre-
sponding to 1 μg of peptide) or control peptide. Blood
pool clearance was measured in five mice injected
with
99mTc-HYNIC-RGD. By 60 to 75 min after injec-
tion, residual blood pool activity was below 10% of peak.
Whole-body planar gamma images in the anteroposter-
ior view were acquired on a high-resolution high-sensi-
tivity dedicated small animal camera with parallel hole
collimator (provided by Jefferson Lab, Newport News,
VA, USA). The camera is based on a 5-in. Hamamatsu
position sensitive photomultiplier type R3292 with an
active field of view of about 95 mm diameter. The scin-
tillator sensor is 1.6-mm-step 6-mm-thick pixelated NaI
(Tl) scintillator array. The photo peak was set at 140
keV with a 15% energy window.
Ex vivo tissue counting
At completion of the imaging session, each animal was
euthanized by an intraperitoneal injection of pentobarbi-
tal (100 mg/kg). The anterior tibialis muscles were dis-
sected, weighed, and counted in a gamma counter
(Wallac Wizard 1470, PerkinElmer, Waltham, MA,
USA) for determination of the percent injected dose of
radiotracer per gram (%ID/g) tissue. The radiotracer
activity in the samples was corrected for background,
decay time, and tissue weight. Limb counting was per-
formed in 28 animals. The remaining animals were used
for immunohistochemistry.
Histopathology
For immunohistochemical analyses, tibialis anterior
muscles were harvested and fixed in 10% formalin for
48 h. Specimens were embedded in paraffin, and tissue
slices (5 μm in thickness) were prepared. Serial sections
were stained with hematoxylin and eosin (H&E) for
morphology. Immunostaining was performed for capil-
lary sprouting using biotinylated Griffonia Bandeiraea
Simplicifolia Isolectin I (Vector Laboratories, Burlin-
game, CA, USA) for b3 ( 1 : 5 0 ;A b c a m ,C a m b r i d g e ,M A ,
USA.) and for aν (1:100; Millipore, Temecula, CA,
USA). Serial sections were also stained for RAGE using
a monoclonal antibody against RAGE (50 μg/ml).
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visualization systems (Vectastain ABC Kit, Vector
Laboratories). All brown staining capillaries were
counted for each of 5 to 6 sections for both the left and
right anterior tibialis muscles for each experiment and
then were averaged. The average number of capillaries
for the left anterior tibialis muscle was divided by the
average number for the right (control) anterior tibialis
muscle. RAGE staining was quantified as area staining
positive for the brown chromagen per 100× field.
Immunofluorescence
Dual immunofluorescent studies were undertaken to
determine the cell types expressing aν integrin. Serial
sections (5 μm in thickness) obtained from the ischemic
hindlimb were deparaffinized in xylene and incubated
with aν (rat anti-mouse integrin aν, 1:100) and co-
stained with endothelial cell marker (FVIII, 1:200) or
macrophage marker (Mac-3, 1:50). Secondary fluores-
cent antibodies were Texas Red anti-rabbit and FITC
anti-mouse. The images were captured and processed
using confocal fluorescence microscope (Nikon, Tokyo,
Japan) and SPOT imaging software (Diagnostic Instru-
ments, Inc., Sterling Heights, MI, USA).
Image analysis
Radiotracer counts in the ischemic hindlimb were deter-
mined from the in vivo scans by using the region of
interest (ROI) method in the mini gamma camera image
using public domain Image J software (NIH, Bethesda,
MD, USA). A region was drawn around the focal
uptake, and the mean counts were determined. Radioac-
tivity in the contralateral control limb was similarly
determined using a comparable ROI (same anatomic
location and the number of pixels). The counts from
each of these areas were used to determine the ischemic
to non-ischemic ratios.
Statistical analysis
Continuous variables were expressed as mean ± stan-
dard deviation. Normality was assessed using the Sha-
piro-Wilk test. Comparisons between two groups were
made using the Student’s t test. Correlation was assessed
using the Pearson product-moment correlation coeffi-
cient. All statistical tests were two-tailed, with P <0 . 0 5
denoting significance. All statistical analyses were per-
formed using STATA 10.1 (StataCorp, College Station,
TX, USA).
Results
Scan analysis
Mean uptake ratios of counts between the left and right
limbs were not different between days 3 and 7 for any
of the four groups: WT non-diabetic (P = 0.52), WT
diabetic (P = 0.39), RAGE
-/- non-diabetic (P = 0.41), and
RAGE
-/- diabetic (P = 0.39). Therefore, days 3 and 7
data were combined as the early time period.
Representative scans from the four groups and the
control peptide are shown in Figure 1. All scans in the
non-diabetic WT group were positive visually, while
three of the left limbs in the diabetic group were nega-
tive, one was equivocal, and one weakly positive. Scans
of the WT mice injected with control peptide showed
no tracer uptake in either limb.
Data from scans and ex vivo well counting for both
hindlimbs are shown in Figure 2. For the WT non-dia-
betic group, the mean scan count ratio for L/R hin-
dlimbs was 1.91 ± 0.34 (range, 1.46 to 2.79), and for the
WT diabetic group, it was 1.38 ± 0.26 (range, 1.05 to
1.74) (P < 0.001) (Figure 2A). The mean value for the
RAGE
-/- non-diabetic group was 2.02 ± 0.29 (range, 1.54
to 2.62) not statistically significantly different from the
WT non-diabetic group. The mean value for the
RAGE
-/- diabetic group was 1.75 ± 0.22 (range, 1.53 to
2.35) which was significantly lower than the RAGE
-/-
non-diabetic group (P < 0.001) and was significantly
higher than the WT diabetic group (P < 0.001).
F i g u r e2 Bs h o w sv a l u e sa s% I D / gf o rt h ef o u rg r o u p s
for the left and right hindlimbs. The counts in the left
(ischemic) hindlimbs showed the same pattern of dif-
ferences among the four groups as shown for the scan
ratios except for values for the WT diabetic and
RAGE
-/- diabetic (1.42 and 1.43). However, the ratios
of L/R hindlimb %ID/g for RAGE
-/- diabetic was
higher than for WT diabetic (2.85 ± 0.40 vs. 2.13 ±
0.67, P = 0.03) (Figure 2C). This difference is due to
lower mean %ID/g in the right limb for RAGE
-/- dia-
betic group. For the remaining limb ratios for %ID/g
values, WT non-diabetic was significantly higher than
WT diabetic (3.04 ± 0.95 vs. 2.13 ± 0.67, P =0 . 0 3 )
and RAGE
-/- non-diabetic was higher than RAGE
-/-
diabetic (4.08 ± 1.00 vs. 2.85 ± 0.40, P = 0.02). All of
these significance levels for intergroup differences
were lower than for the scan data (Figure 2A) possibly
due to the technical challenge to cleanly dissect the
anterior tibialis muscles in the mouse. This limitation
may have weakened the correlation for the plot of the
ratios of L/R limbs against %ID/g (R = 0.059),
although the correlation is highly significant (P =
0.001) (Figure 3).
Histopathology
Examples of tissue sections stained for H&E, aν, b3,a n d
lectin are shown in Figure 4A. Quantitative lectin stain-
ing for capillaries from anterior tibialis muscle sections
(n = 20 per group) for both the left (ischemic) and right
(sham operated) hindlimbs of WT non-diabetic, WT
diabetic, RAGE
-/- non-diabetic, and RAGE
-/- diabetic are
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the WT non-diabetic left limbs was significantly lower
than the RAGE
-/- non-diabetic left limbs (P =0 . 0 5 )a n d
significantly higher than the WT diabetic left limbs (P <
0.001). The capillary staining for the WT diabetic left
limbs was borderline significantly lower than for the
RAGE
-/- diabetic left limbs (P = 0.06). These histological
results support the scan findings. Co-staining of sections
for both endothelial cells and macrophages showed
colocalization with aν (Figure 5).
RAGE staining also supported the scan findings. There
was positive staining for RAGE in the ischemic sections
of hindlimbs from both diabetic and non-diabetic mice,
and no staining in the contralateral control limbs (Fig-
u r e6 ) .T h eR A G E
-/- mice both non-diabetic and dia-
betic showed no RAGE staining.
Discussion
In this study, we used radiolabeled RGD targeting integ-
rin expression and in vivo gamma imaging to look at
the effects of both diabetes and RAGE expression on
the angiogenic response to hindlimb ischemia in mice.
By measuring the ratio of tracer uptake in the ischemic
limb to the contralateral control limb, we were able to
show in live animals that in the absence of RAGE, the
angiogenic response to ischemia is ameliorated both in
diabetic and non-diabetic mice.
Diabetics have an attenuated angiogenic response to
tissue hypoxia which contributes to long-term complica-
tions including poor collateral formation in the heart
and in the lower extremities which is further aggravated
by poor wound healing and ulcers. Several factors have
been identified that contribute to this impaired angio-
genic response in diabetics which include maladaptive
regulation of vascular endothelial growth factor (VEGF)
ligand signaling [10-12], impaired release of endothelial
progenitor cells from the bone marrow [13], and defec-
tive function of the released cells [13,14]. Shoji and co-
workers using a matrigel patch model showed that the
RAGE system is involved in impaired angiogenesis in
diabetes [4].
Under hypoxic conditions, the expression of hypoxia
inducible factor (HIF-1) is increased which turns on
several genes including genes that code for VEGF that
promote angiogenesis to restore perfusion and nor-
moxia in normal subjects. However, exogenous VEGF
has no effect to restore blood flow to diabetic mice
with limb ischemia and there is reduced downstream
VEGF signaling in diabetic animals [10-12]. Tamarat
and co-investigators proposed a mechanism involving
Figure 1 Representative scans from the four groups and the control peptide. Images from each of the four groups of mice injected with
99mTc cyclo-RGD and imaged on days 3 to 7 after left femoral artery ligation with mean values for ratios for L/R hindlimb below each image.
Image in the right shows a representative scan from an animal injected with control peptide. The yellow arrows point to the tracer uptake. The
color table shows the highest counts in red through purple to blue and green is background. The bladder is labeled.
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proteolytic enzymes that degrade the extracellular
matrix, a process that is necessary for the sprouting
capillaries as the neovascular mass grows [5]. After 3
days of limb ischemia following femoral artery ligation,
MMP-2, MMP-3, and MMP-13 were increased in dia-
betic mice compared to controls, but collagenolysis
was decreased, indicating a suppression of the
response. Treatment with aminoguanidine, a thiamine
derivative known to inhibit three of the major bio-
chemical pathways in the pathways of angiogenesis
including AGE formation, restored the collagenolysis
process [5]. Tchaikovski and co-workers investigated
mechanisms whereby AGEs and RAGE expression
inhibit the response of circulating macrophages and
progenitor cells to promote angiogenesis in limb ische-
mia in diabetes and found activation of VEGFR-1-
related signal transduction pathways in monocytes
making them resistant to stimulation by VEGF-A [6].
Shen and co-workers showed that both diabetic and
Figure 2 Data from scans and ex vivo well counting for both hindlimbs.( A) Bars represent mean ± standard deviation values for the ratios
of left/right (L/R) hindlimbs from the scan count data. (B) Bars represent mean ± standard deviation values for %ID/g for both the left and right
legs. (C) Bars in graph represent mean ± standard deviation values for the ratios for %ID/g for L/R hindlimbs. WT, wild-type; DM, diabetes
mellitus; NDM, non-diabetes mellitus.
Figure 3 Correlation of ratio of counts in L/R hindlimb.F r o m
ROIs drawn on the scans correlated with counts from ex vivo
gamma well counting of the muscles from the left and right
hindlimbs and corrected for decay and expressed as %ID/g of
tissue.
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tion from RAGE
-/- donors had improved limb blood
flow at 28 days following ligation compared to mice
receiving marrow from RAGE
+/+ donors [8].
Integrins are cell adhesion receptors expressed on
endothelial cells, and avb3 integrin is responsible for
cell-cell interaction and the interaction between cells
and the extracellular matrix, processes that are neces-
sary for angiogenesis [15-18]. Upon activation of the
complex tertiary structure, integrins unfold, revealing a
recognition site for the Arg-Gly-Asp (RGD) sequence
to bind extracellular matrix (ECM) proteins such as
vitronectin, fibrinogen, and fibronectin [19]. This
unique peptide binding site was used to develop linear
and cyclic peptides with RGD sequence to target avb3
integrin for imaging [19,20]. Because avb3 integrin is
expressed on both endothelial cells and monocyte/
macrophages and the inflammatory response to ische-
mia is increased in diabetes, angiogenesis based on
uptake of
99mTc-HYNIC-RGD in the ischemic hin-
dlimbs may have been overestimated in the diabetic
mice. Nevertheless, the diabetic mice had significantly
lower uptake of
99mTc-HYNIC-RGD in the ischemic
limb compared to the non-diabetic mice, suggesting
that the binding to endothelial cells in this model had
the dominant effect.
Using an RGD mimetic peptide (
99mTc-NC100692),
Hua and colleagues imaged avb3 expression in a murine
limb ischemia model [21]. Integrin expression has also
been targeted for in vivo nuclear imaging in myocardial
infarction and remodeling and in response to VEGF
therapy in chronic low flow dysfunctional myocardium
[22,23]. Our study extends these reports to document
the value of this imaging approach to molecular path-
ways involved in diabetes.
Conclusions
We confirmed in live animals the role of RAGE expres-
sion to inhibit the angiogenic response to limb ischemia
in diabetes. Both the diabetic and non-diabetic RAGE
-/-
mice showed improved angiogenesis compared to the
RAGE
+/+ mice (WT diabetic and non-diabetic) based on
Figure 4 Tissue sections stained for H&E, aν, b3, and lectin.( A) An example of histological and immunohistochemical staining for anterior
tibialis muscle sections for a wild-type non-diabetic mouse. (B) The bar graph for quantitative lectin staining. Each bar represents average ± SD
of lectin-stained capillaries from sections of left anterior tibialis (ischemic limb) (light gray bars) and right anterior tibialis muscle (sham surgery)
(dark gray bars) for animals from each of the four groups.
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Page 6 of 9Figure 5 Dual immunofluorescent staining for cells expressing av in ischemic limb sections.S i t e so fav expression were shown to be
mainly endothelial cells based on colocalization of av (Texas Red) with FVIII (green, fluorescein isothiocyanate) in the merged image.
Colocalization of av with macrophages (Mac-3, fluorescein isothiocyanate) was also seen in the merged image. Areas in yellow represent
colocalization. EC, endothelial cells. (Magnification ×200).
Figure 6 Representative sections of anterior tibialis muscles stained for RAGE (brown chromagen) and displayed at 20×.T h el e f ts e to f
images shows sections from a left (L) ischemic hindlimb (top) and control right (R) limb (bottom) from a WT non-diabetic (NDM) mouse 7 days (D)
after femoral artery ligation. The center set of images shows sections from a left ischemic hindlimb (top) and control right limb (bottom) from a WT
diabetic (DM) mouse 7 days after femoral artery ligation. The right set of images shows sections from a left ischemic hindlimb from a RAGE
-/- non-
diabetic mouse at day 7 after femoral artery ligation (top) and from a RAGE
-/- diabetic mouse at day 7 after femoral artery ligation (bottom).
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expression, a biomarker of tissue changes accompanying
early angiogenesis. While femoral artery occlusion in a
mouse is a simple model for limb ischemia compared to
t h es l o w l yp r o g r e s s i v ed i s ease in humans, the results of
this study support the value of radiolabeled RGD as a
non-invasive tool to follow the angiogenic response to
modifications in factors affecting the angiogenic
response to tissue hypoxia.
Limitations
Planar imaging was used. As reported in a similar model,
planar imaging tends to underestimate relative uptake
within lower limbs as compared with SPECT and gamma
well counting [21]. Since all experiments were performed
the same way, differences among groups are probably not
affected; however, such an underestimation would
explain the slope of the regression line for the plot of %
ID from the scans vs. %ID/g from the tissue.
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